Researchers are exploring a novel quintuple agonist that targets five pathways, including GLP-1R, GIPR, and three PPARs. This ...

Much excitement has built in recent years on the new class of incretin drugs that include glucagon-like-peptide-1 inhibitor ...

Medical experts discuss whether GLP-1 medications, including Mounjaro and Zepbound, could become comprehensive treatments for ...

Dr Shivani Misra is a clinical associate professor and honorary consultant in diabetes at Imperial College London ...

Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURPASS-PEDS, the first Phase 3 trial to evaluate the ...

A compound comprising five agonists that together tackle weight loss, glucose reduction, insulin sensitization, and blood fat ...

Ozempic, marketed by Novo Nordisk in India, is primarily indicated for the treatment of type 2 diabetes. While it can lead to ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes medications — also known as GLP-1 and GIP injections — are changing the way we ...

The WHO has added GLP-1 agonists to its Essential Medicines List in 2025. Learn more about the impact of this decision.

Interest in GLP-1 medications like Ozempic will continue to grow given the multiple health conditions they can improve. In recent years, the growing list of medical benefits for GIP and GLP-1 agonists ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Weight loss can be a challenge, even for those who eat ...

BERLIN — A novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist combined into a single drug (LY3298176, Lilly), dubbed a "twincretin," ...